Investment area
Growth Investments
Region
Europe
Date of investment
January 2023
Evosep is the leading platform offering a high-sample-throughput capability with excellent reproducibility (i.e., valuable, useable data) between sample runs and across instruments and sites. Evosep’s technology shapes the potential of proteomics by developing valuable applications, enabling widespread use, and the development of clinically meaningful protein-based diagnostics.
Contact
Stephen van Helden
Partner
Departments: Planetary Health Investments, Novo Holdings US Inc.
Stephen joined Novo Holdings in 2022.
Prior to joining Novo Holdings, Stephen spent over 5 years developing new products, partnerships and businesses at The Production Board as an EIR, and Zymergen where he led many Industrial efforts including across Agriculture, Food and Packaging. He previously worked with McKinsey and Company as an Associate Partner across a number of sectors and geographies.
Stephen holds an MBA from Stanford University and a BSc in Electrical Engineering from the University of Cape Town.
